• B. fragilis and Gut-Brain Cholinergic Seizure Control

  2026-09-29

  Jia et al. identify a gut–vagus–brain cholinergic circuit through which Bacteroides fragilis suppresses seizures in mouse models and improves outcomes in a pediatric refractory epilepsy trial. The study connects colonic ChAT-positive cells, vagal signaling, and intestinal Lactobacillus enrichment, providing a mechanistic framework for microbiota-targeted antiseizure research.

• Oltipraz Workflows for Nrf2 Liver Research

  2026-09-28

  Oltipraz provides a defined small-molecule way to interrogate Nrf2-driven phase II enzyme induction in liver and MASLD-related models. This workflow pairs concentration-controlled Nrf2 assays with autophagy and ferroptosis readouts inspired by recent Qushi Huoxue ointment research, while preserving clear limits on what can be attributed to a single compound.

• How Isochlorogenic Acid A Disrupts HBV Replication

  2026-09-28

  A study in Antiviral Research finds that isochlorogenic acid A affects several stages of the hepatitis B virus life cycle, including viral gene expression, genome maintenance, and particle assembly. Its effects are associated with HO-1 upregulation and altered intracellular reactive oxygen species, suggesting a host redox pathway worth investigating while leaving the exact causal steps to be resolved.

• 1,2-Dioleoyl-sn-glycero-3-PE (DOPE) Workflow

  2026-09-27

  DOPE is a helper phospholipid for researchers building cationic liposomes and other lipid formulations for nucleic acid delivery, where it may support endosomal membrane fusion and cytoplasmic release. It is not water-soluble and should not be treated as a stand-alone aqueous transfection reagent; prepare it in a compatible organic solvent and evaluate it within the complete formulation.

• Ribonuclease R (RNase R) (20 U/μL) Workflows

  2026-09-26

  Learn how RNase R can support circular RNA enrichment and interpretation of cell-based cancer studies without confusing RNA analysis with direct viability measurement. This practical guide covers controls, workflow limits, and product-selection considerations for SKU K3061.

• Spiroplasma Entry into S2 Cells: Two Uptake Routes

  2026-09-25

  Wei and colleagues established a Drosophila Schneider 2 (S2) cell model and found that Spiroplasma eriocheiris entry depends on clathrin-mediated endocytosis and macropinocytosis, with cytoskeletal components also contributing. The inhibitor-based evidence offers a framework for studying bacterial uptake in an invertebrate cell model, while requiring careful interpretation because pharmacological perturbations do not identify a single molecular target by themselves.

• HA Tag Peptide for Protein Elution Workflows

  2026-09-25

  Use the HA tag peptide to competitively elute HA-tagged proteins from anti-HA capture reagents without relying on harsh elution conditions. This guide connects practical immunoprecipitation choices to research on NEDD4L, PRMT5, and colorectal cancer liver metastasis while distinguishing workflow suggestions from findings reported in the study.

• CUDC-907: Dual PI3K and HDAC Workflow

  2026-09-24

  CUDC-907 is a dual PI3K and HDAC inhibitor for in vitro studies that need to examine signaling, acetylation, cell-cycle, and apoptosis readouts together. Use it in controlled research workflows—not for diagnostic, therapeutic, or clinical applications—and interpret the supplied activity values as product-dossier information rather than paper-specific evidence.

• Transient Cas9 Delivery: From RNA Chemistry to Editing

  2026-09-24

  How SpCas9 mRNA chemistry, delivery conditions, and repair biology shape a more interpretable CRISPR-Cas9 genome editing strategy.

• A-1210477: MCL-1 Inhibitor Workflow

  2026-09-24

  Use A-1210477 to test whether cancer-cell survival depends on MCL-1, then verify that reduced viability reflects mitochondrial apoptosis rather than a nonspecific assay effect. This practical workflow connects dose response, BAX/BAK-dependent mechanism, and combination testing while distinguishing cell-based research from in vivo claims.

• Grazoprevir hydrate: Reliable HCV Assays

  2026-09-23

  This scenario-driven guide explains how Grazoprevir hydrate, SKU C8713, can support better HCV replication and cell-response experiments. It distinguishes antiviral potency from cytotoxicity, outlines practical assay parameters, and provides evidence-based guidance for selecting and handling MK-5172 hydrate.

• Electrical Stimulation Promotes Nanoparticle Uptake

  2026-09-22

  The reference study shows that alternating-current electrical stimulation increases magnetic nanoparticle endocytosis in several cancer cell models without requiring particle surface functionalization. Its evidence connects enhanced uptake with macropinocytosis, reduced F-actin content, and elevated intracellular Ca2+, while functional assays indicate improved magnetic hyperthermia and MRI performance.

• Duplex ddPCR for Long Self-Amplifying RNA QC

  2026-09-22

  Casmil, Huang, and Blakney developed a duplex reverse-transcription droplet digital PCR workflow for absolute measurement of long self-amplifying RNA and estimation of transcript integrity. The study shows how linked 5′ and 3′ measurements, careful control of reverse-transcription format, and orthogonal capillary gel electrophoresis can improve quality assessment and replication-kinetics analysis.

• Thiamet G Workflows for O-GlcNAc Research

  2026-09-21

  Thiamet G provides a practical way to raise protein O-GlcNAcylation while connecting mechanistic studies with tau, bone, and leukemia workflows. This guide covers dose-finding, assay selection, controls, and troubleshooting so researchers can distinguish pathway engagement from nonspecific toxicity.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer

  2026-09-21

  This FASEB Journal study develops chemically modified p21 mRNA-loaded lipid nanoparticles for localized intravesical treatment of bladder cancer. Its findings connect restoration of nuclear p21 with cell-cycle suppression, DNA-damage signaling, apoptosis, and tumor control in an orthotopic mouse model, while highlighting the need to separate promising delivery data from clinical validation.

8024 records 1/535 page Next 12345 下5页 Last page